1p36−, intact P53, and amplified MYCN (CHP-212)
1p36−, mutated P53, and normal MYCN status (SK-N-AS)
1p36−, P53 null mutation, and amplified MYCN (LAN-1)
37 C (Control vs Total fragmented RNA)
42 C
42C for 15min vs 37C at 5min
42C for 30min vs 37C for 5 min
4Gy IR vs Control - Controlling for cell line differences
ABBV-075 vs DMSO - Controlling for cell line differences
ABBV-744 vs DMSO - Controlling for cell line differences
acquired BCR-ABL independent resistance following culture in ponatinib.
AICAR vs DMSO - Controlling for mutation differences
Azacitidine vs Untreated 125nM - Controlling for cell line differences
Azacitidine vs Untreated 250nM - Controlling for cell line differences
Azacitidine vs Untreated 500nM - Controlling for cell line differences
Azacitidine vs untreated in HH cells - Controlling for concentration differences
Azacitidine vs untreated in PF382 cells - Controlling for concentration differences
Azacitidine vs untreated in TLOm1 cells - Controlling for concentration differences
BIX vs DMSO - Controlling for SMYD2 mutation status
BMI-1 over-expression
BRD4 Knockdown vs Non-targetting control - controlling for cell line differences
CC-122 is a direct descendent of thalidomide and lenalidomide
CD45+ Cells isolated from AML xenografts; TRC105 (anti-human CD105 antibody)
Cell Specific IC50 dosage
Chloramphenicol vs DMSO - Controlling for mutation differences
Chromosome 17 Loss
Concentrations (0.3uM, 1uM, 3uM) for 6 and 24 hrs
Contrast time_hr mislabelled
Cyclocreatine vs Control - Controlling for cell line differences
DAC (20 mg/m2/day i.v.) for 5 days every 28 days for at least 3 cycles
DAC vs Control - Controlling for cell line differences
Decitabine 100 nM vs DMSO - Controlling for cell line differences
Decitabine 300 nM vs DMSO - Controlling for cell line differences
Decitabine vs DMSO - Controlling for cell line differences and DAC conc.
Decitabine vs DMSO - Controlling for cell line differences; (A549, H1299, CL1-0, CL1-5, H1792, PC9); Only one replicate per cell line
Decitabine vs DMSO - Controlling for cell line differences; No publication and limited metadata
Decitabine vs Untreated 12.5nM - Controlling for cell line differences
Decitabine vs Untreated 25nM - Controlling for cell line differences
Decitabine vs Untreated 5nM - Controlling for cell line differences
Decitabine vs untreated in HH cells - Controlling for concentration differences
Decitabine vs untreated in PF382 cells - Controlling for concentration differences
Decitabine vs untreated in TLOm1 cells - Controlling for concentration differences
Dox vs Control - Controlling for cell line and mutation differences
Dox vs Control - Controlling for cell line differences
doxorubicin-hydrochloride
Doxycycline induced KRAS G12V
doxycycline-inducible shRNA system to reduce BRD4
Drug Tolerant Persister
Drug Tolerant Persister vs DMSO Control
DU145-resistant vs sensitive
Ebola infected cell line
Etoposide vs Control - Controlling for cell line differences
Etoposide vs Control - Controlling for cell lines differences
fasting medium vs normal culture
Fibroblast patient cell lines carrying mutations in complex I genes NDUFS2 and ND5; OXPHOS deficiency
HPV16 E2 Overexpression
incubated with two dosages of FB23-2, and the known histone demethylase inhibitors JIB-04
JQ1 vs DMSO - Controlling for cell line differences
Long term culture (9 mo) in CP1203; BETi resistant clone vs DMSO in resistant clone
Long term culture (90 days) in CP1203; BETi resistant clone vs DMSO in resistant clone
Manuscript states different concentration than sample metadata. Use manuscript concentration
mesenchymal
Mitomycin C vs No Treatment - Controlling for cell line differences
MMS vs Control - Conntrolling for cell lines differences
Multiple cell lines - JQ1 vs DMSO controlling for cell line
NB4 and Kasumi-1
No publication and limited metadata
Non-Hodgkin's lymphoma cell line; No publication and limited metadata
OXPHOS deficiency
Paclitaxel vs Control - Controlling for cell line differences
Parental cell line
Parental cell line vs DMSO
PC3-resistant vs sensitive
PDX T-ALL
proneural
QuantSeq 3’ mRNA Sequencing REV
Radiation
Rapamycin vs DMSO - Controlling for SMYD2 mutation status
RARGWT S427L
RARGWT S427L Repaired
Resveratrol vs DMSO - Controlling for mutation differences
retroviral overexpression of Myc
Sequential treatment (azacitidine for day 1 to day 4 and BAY1436032 for day 5 to day 9)
sgCLPB1 vs sgRosa
sgINTS6
sgSCR
Simultaneous treatment (azacitidine for day 1 to day 4 and BAY1436032 for day 1 to day 5)
siRNA targeting of E2 reversed repression of E2 targed genes
THZ1 vs Control - Controlling for cell line
TMZ-resistant cell line vs non-resistant
TNFa + transfection with siRNA and GapmeR
transfection with siRNA and GapmeR
Two and half (2.5) liters of boiling water were added to 100 g crushed leaf material and the mixture was stirred for 16 h at room temperature
Venetoclax Resistant Cell Line
Venetoclax-resistant cell line
Vorinostat resistant HCT-116
WT + KO Dox vs Control
xenograft